Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma.


Journal

European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 18 05 2019
accepted: 26 07 2019
revised: 03 07 2019
pubmed: 6 9 2019
medline: 5 6 2020
entrez: 6 9 2019
Statut: ppublish

Résumé

The limited positive predictive value of an incomplete response on PET-CT following (chemo)radiotherapy for head and neck squamous cell carcinoma (HNSCC) means that the optimal management strategy remains uncertain. The aim of the study is to assess the utility of a 'second-look' interval PET-CT. Patients with HNSCC who were treated with (chemo)radiotherapy between 2008 and 2017 and underwent (i) baseline and (ii) response assessment PET-CT and (iii) second-look PET-CT following incomplete (positive or equivocal scan) response were included. Endpoints were conversion rate to complete response (CR) and test characteristics of the second-look PET-CT. Five hundred sixty-two patients with HNSCC underwent response assessment PET-CT at a median of 17 weeks post-radiotherapy. Following an incomplete response on PET-CT, 40 patients underwent a second-look PET-CT at a median of 13 weeks (range 6-25) from the first response PET-CT. Thirty-four out of 40 (85%) patients had oropharyngeal carcinoma. Twenty-four out of 40 (60%) second-look PET-CT scans converted to a complete locoregional response. The primary tumour conversion rate was 15/27 (56%) and the lymph node conversion rate was 14/19 (74%). The sensitivity, specificity, positive predictive value and negative predictive value (NPV) of the second-look PET-CT were 75%, 75%, 25% and 96% for the primary tumour and 100%, 92%, 40% and 100% for lymph nodes. There were no cases of progression following conversion to CR in the primary site or lymph nodes. The majority of patients who undergo a second-look PET-CT convert to a CR. The NPV of a second-look PET-CT is high, suggesting the potential to avoid surgical intervention. • PET-CT is a useful tool for response assessment following (chemo)radiotherapy for head and neck squamous cell carcinoma. • An incomplete response on PET-CT has a limited positive predictive value and optimal management is uncertain. • These data show that with a 'second-look' interval PET-CT, the majority of patients convert to a complete metabolic response. When there is doubt about clinical and radiological response, a 'second-look' PET-CT can be used to spare patients unnecessary surgical intervention.

Identifiants

pubmed: 31485835
doi: 10.1007/s00330-019-06401-7
pii: 10.1007/s00330-019-06401-7
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1212-1220

Références

Clin Oncol (R Coll Radiol). 2017 Nov;29(11):753-759
pubmed: 28780008
Radiat Oncol. 2011 May 24;6:54
pubmed: 21609453
N Engl J Med. 2016 Apr 14;374(15):1444-54
pubmed: 27007578
Clin Radiol. 2016 Jul;71(7):e171-88
pubmed: 27207376
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Head Neck. 2010 Feb;32(2):253-61
pubmed: 19572281
Oral Oncol. 2018 Mar;78:108-113
pubmed: 29496037
Eur J Nucl Med Mol Imaging. 2016 Apr;43(4):605-8
pubmed: 26732470
J Laryngol Otol. 2016 May;130(S2):S90-S96
pubmed: 27841123
J Am Coll Radiol. 2016 Jun;13(6):743-746.e1
pubmed: 26577876
Clin Oncol (R Coll Radiol). 2019 Apr;31(4):212-218
pubmed: 30553580
Clin Med Insights Oncol. 2017 Jun 14;11:1179554917713005
pubmed: 28659717
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Swiss Med Wkly. 2015 Feb 21;145:w14116
pubmed: 25701645
J Laryngol Otol. 2016 May;130(S2):S75-S82
pubmed: 27841116
Eur J Nucl Med Mol Imaging. 2011 Nov;38(11):2083-95
pubmed: 21853309
J Nucl Med. 2014 Sep;55(9):1411-6
pubmed: 24947059
Head Neck. 2011 Dec;33(12):1675-82
pubmed: 22076976
N Engl J Med. 2016 Aug 4;375(5):491-2
pubmed: 27518681
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1239-47
pubmed: 26707387
Oral Oncol. 2014 Mar;50(3):234-9
pubmed: 24387978
Oral Oncol. 2019 Jan;88:153-159
pubmed: 30616786
Br J Radiol. 2015 Aug;88(1052):20140592
pubmed: 26081447
Head Neck. 2016 Apr;38 Suppl 1:E853-8
pubmed: 25917499
Clin Oncol (R Coll Radiol). 2014 Oct;26(10):636-42
pubmed: 24928558
Head Neck. 2016 Apr;38 Suppl 1:E473-9
pubmed: 25716933

Auteurs

Robin J D Prestwich (RJD)

Department of Clinical Oncology, Leeds Cancer Centre, Leeds, LS9 7TF, UK. Robin.Prestwich@nhs.net.
Level 4, Leeds Cancer Centre, St. James's University Hospital, Beckett St., Leeds, LS9 7TF, UK. Robin.Prestwich@nhs.net.

Moses Arunsingh (M)

Department of Clinical Oncology, Leeds Cancer Centre, Leeds, LS9 7TF, UK.

Jim Zhong (J)

Department of Nuclear Medicine and Radiology, Leeds Cancer Centre, Leeds, UK.

Karen E Dyker (KE)

Department of Clinical Oncology, Leeds Cancer Centre, Leeds, LS9 7TF, UK.

Sriram Vaidyanathan (S)

Department of Nuclear Medicine and Radiology, Leeds Cancer Centre, Leeds, UK.

Andrew F Scarsbrook (AF)

Department of Nuclear Medicine and Radiology, Leeds Cancer Centre, Leeds, UK.
Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH